Total global spending on Covid-19 vaccines is projected to reach $157 billion by 2025, driven by mass vaccination programs underway and “booster shots” expected every two years, according to a report by U.S. health data company IQVIA Holdings Inc. released on April 29.
The likelihood that a coronavirus infection will prove fatal dropped by nearly a third since April due to improved treatment, researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME) said.
U.S. deaths from the coronavirus will reach 410,000 by the end of 2020 and deaths could soar to 3,000 per day in December, the University of Washington’s health institute forecast.
A University of Washington model projects the U.S. death toll from COVID-19 will climb to just above 224,000 by Nov. 1, up 16,000 from a prior forecast, due to rising infections and hospitalizations in many states.
The U.S. Food and Drug Administration approved Bausch Health Companies Inc.’s topical plaque psoriasis treatment Duobrii, which is expected to be a key revenue driver for the company.
Gilead Sciences Inc. announced that the company is providing $17.6 million in grants to 30 organizations in the United States through the Gilead HIV Age Positively initiative.
Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.
Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.
Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.
International aid financing and innovation has helped to save nearly 700 million lives in the past 25 years, but those gains could be lost if momentum and political will wane, global health experts said.